Mivebresib|ABBV-075（ABBV075）|BET/MYC inhibitor

Mivebresib|ABBV-075（ABBV075）|BET/MYC inhibitor

Mivebresib is a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo.

Product Name: Mivebresib(ABBV-075）|Cat No: DC9836|cas: 1445993-26-9|Other Names: ABBV-075; ABBV075; ABBV 075

Mivebresib is a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo. Also a potent inhibitor of MYC and the TMPRSS2-ETS fusion proteins. Mivebresib inhibit DHT-stimulated transcription of AR target genes without significant effect on AR protein expression. In addition to blocking the transcription activation downstream of AR, Mivebresib is also a potent inhibitor of MYC and the TMPRSS2-ETS fusion proteins.

For the research and scientific use only, not for human use!